Safety Concerns Doom Addex's Lead ADX10059 On Eve of Partnership
This article was originally published in The Pink Sheet Daily
Executive Summary
Elevated liver enzymes forced the Swiss biotech to halt a development of its lead compound in chronic indications, but the company insists a back-up shows promise.